Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder. According to the Centers for Disease Control and Prevention (CDC), almost 7 million children aged 3 to 17 have been diagnosed with ADHD. Symptoms of this disorder vary in severity, and around 6 out of 10 children have moderate to severe symptoms.
ADHD’s present treatment is categorized by age group. However, the process involves a combination of behavioral therapies and medication. A recent study published by the CDC on April 2, 2026, suggests that there may be 3 unique subtypes of ADHD. As per CDC researchers, this could mark the beginning of the end for one-size-fits-all ADHD treatments. According to them, each subtype involves unique neural circuits and neurotransmitter systems, so the standard diagnostic process, prescribed stimulants, and doses will vary.Â
The study also focused on the chemical and structural brain patterns of 1,154 patients with ADHD. When the experts examined brain scans and neurochemical signals, they noticed that ADHD didn’t affect everyone’s brain activity in the same way. They further observed that 3 different patterns seemed to emerge. The 3 subtypes of ADHD they noticed are:
- Severe combined with emotional dysregulation
- Predominantly impulsive/hyperactive
- Predominantly inattentive
“Each biotype reveals a unique neurobiological narrative”, said one CDC expert. He explained that the predominantly inattentive variant showed alterations in an area tied to sustained attention and filtering distractions. The predominantly impulsive/hyperactive variant showed disruption in circuitry that governs impulse braking and action regulation. Both align closely with clinical findings observed in previous years. The severe combined variant with emotional dysregulation is where this study breaks new ground. This type showed the most widespread brain changes, the most regular emotional dysregulation over time, and preliminary signs of elevated mood swing comorbidity. All these are underpinned by involvement across dopamine, serotonin, acetylcholine, and histamine pathways.
The CDC researchers note that understanding the 3 new types of ADHD will help them in creating a new path toward developing personalized therapeutic approaches. The correlation between neural networks and 3 biotypes in the new study supports ongoing research on the topic and helps ensure the development of a new, well-managed treatment procedure that provides clear benefits to patients.
For more interesting news and updates on ADHD, including how to treat and manage the disorder with the best treatments and medications, follow Medipedia. We help you stay up to date on the latest news and developments in health, medication, and treatment practices.
Disclaimer:
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication or treatment.